JMP Securities Reiterates Market Outperform on AtriCure, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Daniel Stauder has reiterated a 'Market Outperform' rating on AtriCure (NASDAQ:ATRC) and maintained a price target of $60.
November 29, 2023 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Daniel Stauder has reiterated a 'Market Outperform' rating on AtriCure and maintained a price target of $60.
The reiteration of a 'Market Outperform' rating and the maintenance of a $60 price target by a reputable analyst could positively influence investor sentiment and potentially lead to a short-term increase in AtriCure's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100